Pfizer jab 'stopping 91% of cases in first six months'
April 2, 2021 6:39 am
Pfizer says its vaccine is preventing 91% of coronavirus cases in the six months after people are immunised.
And a separate study shows even people in their 80s and 90s are producing impressive levels of antibodies after receiving both doses of the vaccine.
Only 63% of them, however, also produce the T-cells that help maintain those antibodies in the longer term.
And the crucial question of how long the protection from the vaccine lasts remains unanswered.
Pfizer analysed data from 46,000 people on the original clinical trial, exactly six months after their second dose.
It also looked at 800 trial participants in South Africa and concluded the vaccine was equally effective against the variant identified there – despite laboratory studies suggesting people’s antibodies were less effective at attacking this variant.
“The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine’s overall effectiveness,” chairman and chief executive officer Albert Bourla said.
Similar, long-term studies are taking place for all the vaccines including Oxford-AstraZeneca, but Pfizer has been the first to report.